Hydrocortisone Acetate

Yale scientists have uncovered how the stress hormone cortisol helps the brain turn emotional experiences into stronger, longer-lasting memories. The discovery reveals that stress can reshape communication between brain networks involved in emotion and memory, potentially explaining why certain moments are so difficult to forget.Stress does more than influence how we feel. It can also change what we remember, particularly when an experience is emotionally intense or personally meaningful. Scientists have long known that cortisol, a hormone released during stressful situations, can strengthen emotional memories. What has been less clear is exactly how this happens inside the brain. Researchers at Yale University have now uncovered important clues. Their study reveals that cortisol strengthens emotional memories by changing how brain networks involved in emotion and memory function and communicate with one another. The findings offer a deeper understanding of why certain experiences leave such powerful impressions while others quickly fade. "We all experience stress, and my lab is interested in understanding how stress can be helpful," said corresponding author Elizabeth Goldfarb, an assistant professor of psychiatry at Yale School of Medicine and of psychology in the Faculty of Arts and Sciences. The findings were published in the journal Science Advances. How Stress Hormones Influence Memory Previous research involving both humans and rodents has shown that stress and cortisol can improve memory for emotional events. Scientists also know that certain brain regions, including the amygdala, play an essential role in this process. The amygdala is particularly important for processing emotions and identifying experiences that may be significant. However, understanding precisely how cortisol strengthens memories has been challenging. Many brain regions participate in several mental functions, making it difficult to determine whether the hormone is influencing emotional responses, memory formation, or both. "Forming memories for emotional experiences involves different processes in the brain: first, perceiving an experience as emotional or intense, and second, encoding that experience into long-term memory," said Goldfarb, who is also a member of Yale's Wu Tsai Institute, an interdisciplinary research initiative that explores cognition. The researchers wanted to examine these processes separately to determine how cortisol affects the brain's ability to recognize emotional significance and preserve an experience as a lasting memory. Watching the Brain Form Emotional Memories To investigate, the Yale team conducted an experiment in which participants took a pill containing either hydrocortisone, a form of cortisol, or an inactive placebo. They then viewed a series of pictures while undergoing functional MRI (fMRI) scanning. This imaging technique measures changes in blood flow and oxygen levels associated with brain activity, allowing researchers to identify which areas of the brain are more active during different tasks. As participants examined the pictures, they reported their emotional reactions to each image. The following day, researchers tested how well they remembered what they had seen. Each person completed the experiment twice, once after receiving hydrocortisone and once after receiving the placebo. The study used a double blind design, meaning neither the participants nor the experimenter knew which substance had been administered during a particular session. This approach allowed the scientists to compare how the same person's brain responded with and without the additional cortisol. A Five-Second Look at Brain Network Activity One of the study's most important advances came from the way researchers analyzed the brain scans. Scientists often study a measurement called functional connectivity, which describes how closely activity in different parts of the brain fluctuates together. When two regions show synchronized patterns of activity, it can indicate that they are participating in related processes. Traditionally, examining these relationships requires several minutes of brain imaging data. The Yale team instead analyzed functional connectivity during individual trials lasting only around five seconds. Using these brief snapshots, the researchers tested whether patterns of brain activity could predict two different outcomes: how emotionally intense participants found a picture and whether they would remember that picture the following day. The approach worked for both. By identifying patterns associated with emotional intensity and memory formation separately, the scientists were able to examine how cortisol influenced each network and the interactions between them. This gave the researchers a more detailed picture of the changing brain activity associated with emotional memory formation. Cortisol Changes How Brain Networks Work Together The results revealed two major effects. First, cortisol improved participants' ability to remember emotionally significant experiences, confirming what earlier research had suggested. Second, and more importantly, the hormone strengthened emotional memory through distinct changes in the brain networks responsible for processing emotion and forming memories. In networks associated with emotion, cortisol produced more consistent patterns of activity and increased their engagement. This suggests that the hormone helped the brain respond more strongly and reliably to the emotional significance of an experience. In memory networks, cortisol had a different effect. It made their activity patterns more specialized for emotional information, suggesting that the brain was adjusting how it encoded emotionally meaningful experiences. The hormone also increased coordination between the networks involved in emotion and memory. In other words, cortisol appeared to help these different brain systems work together more effectively when processing experiences that carried emotional weight. Together, these findings suggest that stress strengthens emotional memories through several interacting brain mechanisms rather than through a single region or process. Why Emotional Experiences Can Be So Memorable The results help explain why stress does not necessarily improve memory for everything. Instead, its benefits appear to be selective, making experiences that feel particularly intense or meaningful more likely to be remembered. The researchers believe this reflects the brain's ability to adapt to stressful situations by prioritizing information that may be important. "Stress responses are fundamentally adaptive and can help you form strong memories -- but this is specific to experiences that you find to be emotionally intense or meaningful," Goldfarb said. "This is in part related to your brain increasing engagement of networks that track emotional intensity. So, if you are stressed out and trying to learn something new, it might help to think about exciting elements or strong feelings connected to what you are learning." The findings also point to a potentially useful insight about learning. Connecting information to something exciting, personally important, or emotionally engaging could make it easier to remember, particularly during stressful situations. Rather than simply disrupting memory, stress can sometimes help the brain identify which experiences deserve special attention and strengthen the networks involved in preserving them. Other Yale researchers involved in the study include Rajita Sinha, the Foundations Fund Endowed Professor in Psychiatry and professor in the Child Study Center and of neuroscience at Yale School of Medicine (YSM), and Todd Constable, the Elizabeth Mears and House Jameson Professor of Radiology and Biomedical Imaging and professor of neurosurgery at YSM. The research was supported by grants from the National Institutes of Health.

信源·术语表｜37&38｜麻醉·疼痛·休克·感染·创伤·烧伤·切除·移植｜写给硬核求知者的290万字“麻瓜医学大全”｜第8部（外科学）中卷｜第37&38/40册目录第4章 麻醉、疼痛与围手术期处理4.1 麻醉 4.2 麻醉中的监测 4.3 疼痛治疗 4.4 围手术期处理 4.5 麻醉技术演进 4.6 围手术期边界之争第5章 外科休克、感染与MODS5.1 外科休克 5.2 外科感染 5.3 多器官功能障碍综合征（MODS） 5.4 重症监测 5.5 血液净化 5.6 心肺脑复苏 5.7 危重患者 5.8 液体复苏技术演进 5.9 脓毒症定义之争第6章 急性组织损伤：创伤、烧伤与急腹症6.1 创伤与战伤 6.2 多发伤、创伤、休克与损伤控制 6.3 烧伤与冻伤 6.4 吸入性损伤 6.5 急腹症 6.6 咬伤和叮伤 6.7 断肢断指再植与手外伤 6.8 一个字母改写学科 6.9 损伤控制观念革命 6.10 蛇咬伤第7章 肿瘤切除与器官移植7.1 肿瘤 7.2 肿瘤免疫与肿瘤标志物 7.3 器官移植 7.4 移植类型 7.5 整形、修复及颌面外科 7.6 案例：淋巴结清扫 7.7 案例：一只器官的旅行 7.8 案例：Tim Andrews的271天 7.9 可编程器官：移植vs制造继续麻瓜医学之旅全书索引｜写给硬核求知者的290万字“麻瓜医学大全”（解剖·生理·病理·免疫·诊断·药理·内科·外科） - 周舟的文章 - 知乎全书索引｜写给硬核求知者的290万字“麻瓜医学大全”（解剖·生理·病理·免疫·诊断·药理·内科·外科）信源与说明第4章 麻醉、疼痛与围手术期处理学术论文与专著麻醉前评估与气道管理Apfelbaum JL, Hagberg CA, Connis RT, et al. Practice Guidelines for Management of the Difficult Airway: An Updated Report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Anesthesiology. 2022;136(1):31-81.Frerk C, Mitchell VS, McNarry AF, et al. Difficult Airway Society 2015 guidelines for management of unanticipated difficult intubation in adults. British Journal of Anaesthesia. 2015;115(6):827-848.Difficult Airway Society. DAS Guidelines 2025 Update. British Journal of Anaesthesia. 2025.（2025年更新版指南，将视频喉镜明确为一线插管工具）Hansel J, Rogers AM, Lewis SR, et al. Videolaryngoscopy versus direct laryngoscopy for adults undergoing tracheal intubation. Cochrane Database of Systematic Reviews. 2022;4:CD011136.Cook TM, Woodall N, Frerk C. Major complications of airway management in the UK: results of the Fourth National Audit Project of the Royal College of Anaesthetists and the Difficult Airway Society. British Journal of Anaesthesia. 2011;106(5):617-631.围手术期评估与风险分层Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999;100(10):1043-1049.（RCRI/Lee指数原始文献）Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2014;130(24):e278-e333.Gupta PK, Gupta H, Sundaram A, et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. Circulation. 2011;124(4):381-387.Wijeysundera DN, Pearse RM, Shulman MA, et al. Assessment of functional capacity before major non-cardiac surgery: an international, prospective cohort study. The Lancet. 2018;391(10140):2631-2640.全身麻醉的药理学基础Egan TD. Pharmacokinetics and pharmacodynamics of inhaled anesthetics. Anesthesiology Clinics of North America. 2001;19(4):653-669.Sahinovic MM, Struys MMRF, Absalom AR. Clinical Pharmacokinetics and Pharmacodynamics of Propofol. Clinical Pharmacokinetics. 2018;57(12):1539-1558.Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clinical Pharmacokinetics. 2017;56(8):893-913.肌松拮抗与舒更葡糖Keating GM. Sugammadex: A Review of Neuromuscular Blockade Reversal. Drugs. 2016;76(13):1255-1273.Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetists. British Journal of Anaesthesia. 2006;97(2):123-126.Miyazaki Y, Sunaga H, Kida K, et al. Incidence of Anaphylaxis Associated With Sugammadex. Anesthesia & Analgesia. 2018;126(5):1505-1508.FDA. Sugammadex (Bridion) prescribing information. 2025.（2025年更新版，新增过敏反应警告）椎管内麻醉与抗凝管理Horlocker TT, Vandermeuelen E, Kopp SL, et al. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fifth Edition). Regional Anesthesia & Pain Medicine. 2025;50(2):89-124.（ASRA第5版指南，2025年更新）Gogarten W, Vandermeulen E, Van Aken H, et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. European Journal of Anaesthesiology. 2010;27(12):999-1015.麻醉深度监测Punjasawadwong Y, Phongchiewboon A, Bunchungmongkol N. Bispectral index for improving anaesthetic delivery and postoperative recovery. Cochrane Database of Systematic Reviews. 2014;6:CD003843.Avidan MS, Zhang L, Burnside BA, et al. Anesthesia awareness and the bispectral index. New England Journal of Medicine. 2008;358(11):1097-1108.（BIS监测预防术中知晓的关键RCT）Mashour GA, Shanks A, Tremper KK, et al. Prevention of intraoperative awareness with explicit recall in an unselected surgical population: a randomized comparative effectiveness trial. Anesthesiology. 2012;117(4):717-725.术后疼痛管理Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. Journal of Pain. 2016;17(2):131-157.Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. The Lancet. 2006;367(9522):1618-1625.Joshi GP, Van de Velde M, Kehlet H, et al. Development of evidence-based recommendations for procedure-specific pain management: PROSPECT methodology. Anaesthesia. 2019;74(10):1298-1304.加速康复外科（ERAS）Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. British Journal of Anaesthesia. 1997;78(5):606-617.（ERAS概念奠基性文献）Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. Annals of Surgery. 2008;248(2):189-198.Gustafsson UO, Scott MJ, Hubner M, et al. Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations: 2018. World Journal of Surgery. 2019;43(3):659-695.Ljungqvist O, Scott M, Fearon KC. Enhanced Recovery After Surgery: A Review. JAMA Surgery. 2017;152(3):292-298.ERAS® Society. Guidelines for Perioperative Care in Elective Colorectal Surgery: 2025 Update. Clinical Nutrition. 2025.（2025年更新版，微创手术中胸段硬膜外麻醉不再常规推荐）麻醉监测与报警疲劳The Joint Commission. National Patient Safety Goal on Alarm Management. Joint Commission Perspectives. 2025.Cvach M. Monitor alarm fatigue: an integrative review. Biomedical Instrumentation & Technology. 2012;46(4):268-277.Sendelbach S, Funk M. Alarm fatigue: a patient safety concern. AACN Advanced Critical Care. 2013;24(4):378-386.闭环麻醉与自动化Hemmerling TM, Arbeid E, Wehbe M, et al. Evaluation of a novel closed-loop anesthesia delivery system: a randomized controlled trial. Anesthesiology. 2010;112(1):122-129.Brogi E, Cyr S, Kazan R, et al. Clinical Performance and Safety of Closed-Loop Systems: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Anesthesia & Analgesia. 2017;124(2):446-455.Schamberg G, Barends CRM, Absalom AR, et al. Closed-loop anesthesia: A systematic review and meta-analysis of randomized controlled trials. British Journal of Anaesthesia. 2026;136(4):712-725.（2026年荟萃分析，17项RCT，1898例患者）Pasin L, Nardelli P, Pintaudi M, et al. Closed-Loop Delivery Systems Versus Manually Controlled Administration of Total IV Anesthesia: A Meta-analysis of Randomized Clinical Trials. Anesthesia & Analgesia. 2017;124(2):456-464.GLP-1受体激动剂与围手术期管理Sen S, Potnuru PP, Hernandez N, et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia. JAMA Surgery. 2024;159(6):660-667.Joshi GP, Gitman M, Shah S, et al. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs). Anesthesiology. 2023;139(3):298-306.Kindel TL, Wang AY, Wadhwa A, et al. Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-Like Peptide-1 Receptor Agonists in the Perioperative Period. Surgery for Obesity and Related Diseases. 2025;21(3):245-256.Sherwin M, Hamburger J, Katz D, et al. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study. Canadian Journal of Anesthesia. 2023;70(9):1487-1495.机构报告与指南中华医学会麻醉学分会. 中国麻醉学指南与专家共识（2025版）. 北京: 人民卫生出版社, 2025.中华医学会麻醉学分会. 中国麻醉医生职业现状白皮书. 2024.国家卫生健康委员会. 麻醉科医疗服务能力建设指南（试行）. 2019.ASA House of Delegates. ASA Physical Status Classification System. American Society of Anesthesiologists. 2020.American Society of Anesthesiologists. Standards for Basic Anesthetic Monitoring. 2020.历史文献Warren JC. Diary entry describing the first public demonstration of ether anesthesia at Massachusetts General Hospital, October 16, 1846. Countway Library of Medicine, Harvard Medical School.Long CW. Account of the first use of sulphuric ether as an anaesthetic. Southern Medical and Surgical Journal. 1849;5:705-708.（Crawford Long 1849年首次公开发表其1842年使用乙醚的记录）Morton WTG. Circular announcing the discovery of practical anaesthesia. Boston: 1846.Bigelow HJ. Insensibility during surgical operations produced by inhalation. Boston Medical and Surgical Journal. 1846;35:309-317.（1846年11月发表的关于乙醚麻醉首次公开演示的报道）Robinson DH. The ether controversy. Medical Record. 1890;38:1-12.延伸阅读Snow SJ. Blessed Days of Anaesthesia: How Anaesthetics Changed the World. Oxford University Press, 2008.Fenster JM. Ether Day: The Strange Tale of America’s Greatest Medical Discovery and the Haunted Men Who Made It. HarperCollins, 2001.Gawande A. Complications: A Surgeon’s Notes on an Imperfect Science. Metropolitan Books, 2002.于布为. 麻醉学的历史、现状与未来. 中华麻醉学杂志. 2021;41(1):1-8.新闻报道与评论Mass General Brigham. Ether Day: The 175th Anniversary of Anesthesia. Mass General Brigham News. 2021.Harvard Gazette. Ether Dome at Massachusetts General Hospital still a shrine to anesthesia. Harvard Gazette. 2021.中国医师协会麻醉学医师分会. 中国麻醉学科发展报告. 2025.《医师报》. 缺口30万：如何破解麻醉医师过劳困局. 2025年4月.第5章 外科休克、感染与MODS学术论文与专著休克的定义与病理生理Vincent JL, De Backer D. Circulatory shock. New England Journal of Medicine. 2013;369(18):1726-1734.Cecconi M, De Backer D, Antonelli M, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Medicine. 2014;40(12):1795-1815.Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.（Sepsis-3定义原始文献）Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):762-774.Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):775-787.SOFA-2评分Bhavani SV, Seymour CW, Coopersmith CM, et al. Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score. JAMA. 2025;334(23):2090-2103. doi:10.1001/jama.2025.20516（SOFA-2原始文献，基于全球330万ICU患者数据）Singer M. The New SOFA-2 Score: A Step Forward in Organ Dysfunction Assessment. JAMA. 2025;334(23):2065-2066.液体复苏Bickell WH, Wall MJ Jr, Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. New England Journal of Medicine. 1994;331(17):1105-1109.Dutton RP, Mackenzie CF, Scalea TM. Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. Journal of Trauma. 2002;52(6):1141-1146.Curry N, Hopewell S, Dorée C, et al. The acute management of trauma hemorrhage: a systematic review of randomized controlled trials. Critical Care. 2011;15(2):R92.Roberts I, Shakur H, Coats T, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technology Assessment. 2013;17(10):1-79.脓毒性休克的血压目标Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure target in patients with septic shock (SEPSISPAM). New England Journal of Medicine. 2014;370(17):1583-1593.Lamontagne F, Meade MO, Hébert PC, et al. Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Medicine. 2016;42(4):542-550.免疫抑制与移植相关感染Fishman JA. Infection in Organ Transplantation. American Journal of Transplantation. 2017;17(4):856-879.Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900-931.液体复苏的最新证据ESICM Task Force. European Society of Intensive Care Medicine guidelines on fluid therapy in critically ill patients. Intensive Care Medicine. 2025.（ESICM 2025液体复苏指南，将“至少30ml/kg”改为“至多30ml/kg”）Silversides JA, Major E, Ferguson AJ, et al. Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Medicine. 2017;43(2):155-170.血液净化与CRRTVA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. New England Journal of Medicine. 2008;359(1):7-20.（ATN研究）RENAL Replacement Therapy Study Investigators. Intensity of continuous renal-replacement therapy in critically ill patients. New England Journal of Medicine. 2009;361(17):1627-1638.（RENAL研究）Bellomo R, Cass A, Cole L, et al. Intensity of continuous renal-replacement therapy in critically ill patients. New England Journal of Medicine. 2009;361(17):1627-1638.DICTaylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thrombosis and Haemostasis. 2001;86(5):1327-1330.（ISTH DIC积分系统）Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Journal of Haematology. 2009;145(1):24-33.维生素C与脓毒症Marik PE, Khangoora V, Rivera R, et al. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest. 2017;151(6):1229-1238.Fujii T, Luethi N, Young PJ, et al. Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial. JAMA. 2020;323(5):423-431.（VITAMINS研究，未能证实获益）LOVIT Investigators. Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit. New England Journal of Medicine. 2022;386(25):2387-2398.（LOVIT研究，提示可能有害）机构报告与指南Surviving Sepsis Campaign. International Guidelines for Management of Sepsis and Septic Shock 2021. Critical Care Medicine. 2021;49(11):e1063-e1143.Surviving Sepsis Campaign. Updated Guidelines for Management of Sepsis and Septic Shock 2026. Critical Care Medicine. 2026.（2026年更新版，抗生素时机采用风险分层策略）Clinical Excellence Commission (New South Wales). Sepsis Clinical Pathway — Position Statement on qSOFA. 2016.中华医学会重症医学分会. 中国脓毒症/脓毒性休克急诊治疗指南（2023）. 中华急诊医学杂志. 2023;32(6):721-738.AWMF. S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge. 2025.（德国S3脓毒症指南，2025年更新）延伸阅读Singer M. The Sepsis Text. Springer, 2022.Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014;40(4):463-475.管向东, 陈德昌. 中国脓毒症研究十年. 中华内科杂志. 2020;59(3):161-166.第6章 急性组织损伤：创伤、烧伤与急腹症学术论文与专著ATLS与创伤评估American College of Surgeons Committee on Trauma. Advanced Trauma Life Support (ATLS®) Student Course Manual, 11th Edition. Chicago: American College of Surgeons, 2025.（xABCDE流程原始教材）Galvagno SM Jr, Nahmias JT, Young DA. Advanced Trauma Life Support® Update 2019: Management and Applications for Adults and Special Populations. Anesthesiology Clinics. 2019;37(1):13-32.Mohammad A, Branicki F, Abu-Zidan FM. Educational and clinical impact of Advanced Trauma Life Support (ATLS) courses: a systematic review. World Journal of Surgery. 2014;38(2):322-329.损伤控制外科与损伤控制复苏Stone HH, Strom PR, Mullins RJ. Management of the major coagulopathy with onset during laparotomy. Annals of Surgery. 1983;197(5):532-535.（损伤控制概念的首次描述）Rotondo MF, Schwab CW, McGonigal MD, et al. “Damage control”: an approach for improved survival in exsanguinating penetrating abdominal injury. Journal of Trauma. 1993;35(3):375-382.（“损伤控制”术语的正式提出）Shapiro MB, Jenkins DH, Schwab CW, et al. Damage control: collective review. Journal of Trauma. 2000;49(5):969-978.Duchesne JC, McSwain NE Jr, Cotton BA, et al. Damage control resuscitation: the new face of damage control. Journal of Trauma. 2010;69(4):976-990.创伤性凝血病Brohi K, Singh J, Heron M, et al. Acute traumatic coagulopathy. Journal of Trauma. 2003;54(6):1127-1130.CRASH-2 Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. The Lancet. 2010;376(9734):23-32.CRASH-3 Trial Collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. The Lancet. 2019;394(10210):1713-1723.2025年Critical Care系统综述：早期纤维蛋白原替代与死亡率、DVT或输血需求无显著关联。烧伤面积估算与补液Baxter CR, Shires T. Physiological response to crystalloid resuscitation of severe burns. Annals of the New York Academy of Sciences. 1968;150(3):874-894.（Parkland公式原始文献）American Burn Association. Burn Shock Resuscitation Clinical Practice Guideline. Chicago: American Burn Association, 2024.（2024年ABA指南，将初始复苏剂量建议为2ml/kg/%TBSA）Pham TN, Cancio LC, Gibran NS. American Burn Association practice guidelines: burn shock resuscitation. Journal of Burn Care & Research. 2008;29(1):257-266.Saffle JR. The phenomenon of “fluid creep” in acute burn resuscitation. Journal of Burn Care & Research. 2007;28(3):382-395.烧伤流行病学与中国数据中华烧伤杂志编辑部. 瑞金烧伤专业60周年纪要. 中华烧伤杂志. 2018;34(9):577-584.上海市地方志办公室. 灼伤整形科. 上海地方志·卫生志. 2003.上海交通大学医学院附属瑞金医院烧伤科. 学科发展报告（1958–2018）. 2018.电烧伤与化学烧伤Fish RM. Electric injury, Part I: Treatment priorities, subtle diagnostic factors, and burns. Journal of Emergency Medicine. 1999;17(6):977-983.Palao R, Monge I, Ruiz M, et al. Chemical burns: pathophysiology and treatment. Burns. 2010;36(3):295-304.2025年中国吸入性损伤共识更新：将肺康复纳入推荐。冻伤McIntosh SE, Opacic M, Freer L, et al. Wilderness Medical Society practice guidelines for the prevention and treatment of frostbite: 2019 update. Wilderness & Environmental Medicine. 2019;30(4S):S19-S32.Cauchy E, Cheguillaume B, Chetaille E. A controlled trial of a prostacyclin and rt-PA in the treatment of severe frostbite. New England Journal of Medicine. 2011;364(2):189-190.急腹症与腹膜炎Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World Journal of Emergency Surgery. 2017;12:29.Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clinical Infectious Diseases. 2010;50(2):133-164.消化道出血Barkun AN, Almadi M, Kuipers EJ, et al. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. Annals of Internal Medicine. 2019;171(11):805-822.Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47(10):a1-a46.de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop. Journal of Hepatology. 2015;63(3):743-752.蛇咬伤WHO. Guidelines for the Management of Snakebites, 3rd Edition. Geneva: World Health Organization, 2026.（2026年更新版指南）WHO. Target Product Profiles for Small Molecule or Engineered Antibody Therapeutics for Treatment of Snakebite Envenoming. Geneva: World Health Organization, 2026.（2026年2月发布的首个蛇咬伤新型治疗TPP）Gutiérrez JM, Calvete JJ, Habib AG, et al. Snakebite envenoming. Nature Reviews Disease Primers. 2017;3:17063.Harrison RA, Hargreaves A, Wagstaff SC, et al. Snake envenoming: a disease of poverty. PLoS Neglected Tropical Diseases. 2009;3(12):e569.中国疾病预防控制中心. 中国蛇咬伤流行病学调查报告（2020–2024）. 2025.犬咬伤与狂犬病WHO. WHO Expert Consultation on Rabies, Third Report. Geneva: World Health Organization, 2018.Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. The Lancet Infectious Diseases. 2002;2(6):327-343.虫蜇伤Golden DB, Demain J, Freeman T, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Annals of Allergy, Asthma & Immunology. 2017;118(1):28-54.断肢再植与手外伤陈中伟, 钱允庆. 前臂完全性创伤性截肢再植成功. 中华医学杂志. 1963;49(6):355-358.（1963年世界首例前臂完全性创伤性截肢再植报告）Tamai S. History of microsurgery — from the beginning until the end of the 1970s. Microsurgery. 1993;14(1):6-13.赵建文, 等. 0.2毫米血管吻合的临床经验. 中华显微外科杂志. 2020;43(2):115-119.机构报告与数据国家卫生健康委员会. 2025年中国器官捐献与移植工作报告. 2026.中国人体器官捐献管理中心. 2025年度工作报告. 2026.TCCC Committee. Tactical Combat Casualty Care Guidelines 2025. Journal of Special Operations Medicine. 2025.WHO. Snakebite Envenoming Fact Sheet. Geneva: World Health Organization, 2026.American Burn Association. National Burn Repository 2024 Report. 2024.The Joint Commission. National Patient Safety Goal on Alarm Management. 2025.延伸阅读Manring MM, Hawk A, Calhoun JH, et al. Treatment of war wounds: a historical review. Clinical Orthopaedics and Related Research. 2009;467(8):2168-2191.Pruitt BA Jr, Wolf SE, Mason AD Jr. Epidemiological, demographic, and outcome characteristics of burn injury. Total Burn Care. 2012:14-32.盛志勇, 郭振荣. 烧伤学. 上海: 上海科学技术出版社, 2020.第7章 肿瘤切除与器官移植学术论文与专著肿瘤外科原则Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, 8th Edition. New York: Springer, 2017.Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. Journal of the National Cancer Institute. 2001;93(8):583-596.2025年ESMO指南：围手术期免疫治疗在胃癌/胃食管结合部癌中的应用。淋巴结清扫与前哨淋巴结活检Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918-926.（Z0011试验10年随访结果）Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-575.（Z0011试验首次报告）Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine. 2017;376(23):2211-2222.（MSLT-II试验）Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. The Lancet Oncology. 2016;17(6):757-767.器官保存与移植2025年RCT荟萃分析：NMP vs SCS in Liver Transplantation. 4项RCT，801例患者。2025年JAMA Network Open：DHOPE-PRO与日间肝移植的队列研究。2026年Nature子刊综述：NMP将保存从被动储存转变为主动的生理性干预。免疫抑制KDIGO. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Transplantation. 2009;9(Suppl 3):S1-S155.2025年Am J Transplant：MDR-101临床试验，肾移植受者达到供体混合嵌合体和功能性免疫耐受超过2年。器官分配与MELD评分Wiesner R, Edwards E, Freeman R, et al. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91-96.UNOS/OPTN. Policy 9: Allocation of Livers and Liver-Intestines. 2023.中国人体器官分配与共享计算机系统（COTRS）技术规范. 2024.移植伦理WHO. WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation. Geneva: World Health Organization, 2010.Abouna GM. Ethical issues in organ transplantation. Medical Principles and Practice. 2003;12(1):54-69.异种移植与Tim Andrews案例Riella LV, et al. Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study. The Lancet. 2026.（Tim Andrews案例正式论文，2026年9月发表）Mass General Brigham. How a pig-kidney xenotransplant served as a successful bridge to human transplant for patient with end-stage kidney disease. Mass General Brigham News. 2026-09-04.西京医院. 亚洲首例基因编辑猪-人肾移植. 2025-03-06.2026年西京医院亚洲第二例异种肾移植. 2026-04-23.《科学》2025年度十大科学突破：异种移植评述. 2025-12.3D生物打印与CAR-T付小兵院士团队. 3D生物打印功能性皮肤组织修复难愈性创面. Journal of Investigative Dermatology. 2025.章少锟, 等. 血管化人工皮肤的生物3D打印：从工艺创新到临床应用进展. International Journal of Extreme Manufacturing. 2026.科济药业. 舒瑞基奥仑赛（CT041）治疗晚期胃/食管胃结合部腺癌的临床试验结果. 2026.《华尔街日报》. 欧美患者赴中国接受CAR-T治疗. 2026-09.2026年BioCon China Expo第十三届国际生物药技术年会：体内CAR-T专场. 2026-09.PSA筛查与过度诊断Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. New England Journal of Medicine. 2009;360(13):1320-1328.（ERSPC研究）Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. Journal of the National Cancer Institute. 2012;104(2):125-132.（PLCO研究）Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. European Urology. 2014;65(6):1046-1055.机构报告与数据国家药品监督管理局. 舒瑞基奥仑赛注射液（恺力美/CT041）批准上市公告. 2026-06-22.国家医保局. 手术和治疗辅助操作类医疗服务价格项目立项指南（试行）. 2026-01.中国人体器官捐献管理中心. 2025年度数据报告. 2026.UNOS. Organ Procurement and Transplantation Network: Policy and Data. 2025.WHO. Global Observatory on Donation and Transplantation. 2024.中国临床肿瘤学会（CSCO）. 乳腺癌诊疗指南2025. 2025.延伸阅读Mukherjee S. The Emperor of All Maladies: A Biography of Cancer. Scribner, 2010.Gawande A. Being Mortal: Medicine and What Matters in the End. Metropolitan Books, 2014.Starzl TE. The Puzzle People: Memoirs of a Transplant Surgeon. University of Pittsburgh Press, 1992.王正昕, 等. 中国器官移植发展报告（2025）. 北京: 人民卫生出版社, 2026.中卷结语综合参考与延伸阅读Gawande A. The Checklist Manifesto: How to Get Things Right. Metropolitan Books, 2009.（“现代医学最大的问题不是我们不知道做什么，而是我们常常不能把我们已知的东西正确地付诸实施”出处）葛文德. 最好的告别：关于衰老与死亡，你必须知道的常识. 杭州: 浙江人民出版社, 2015.《科学》2025年度十大科学突破评述. Science. 2025-12.2025年《柳叶刀》创刊200周年专题：外科的过去、现在与未来。数据与统计来源GBD 2017 Sepsis Collaborators. Global, regional, and national sepsis incidence and mortality, 1990–2017. The Lancet. 2020;395(10219):200-211.Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet. 2020;395(10219):200-211.WHO. Snakebite Envenoming Fact Sheet. Geneva: World Health Organization, 2026.中国器官移植发展基金会. 2026年中国器官捐献主题活动日发布数据. 2026-06-11.河北省卫生健康委员会转引中国器官移植发展基金会数据. 2026-06.中国医师协会麻醉学医师分会. 中国麻醉医生职业现状白皮书. 2024.全文核心术语表总论与跨章概念代谢时钟（Metabolic Clock）外科学中一个贯穿性的分析框架：每一项外科干预都发生在一个不可协商的生理倒计时之内。供肝能耐受冷缺血约12小时，供心约6小时，断肢肌肉在室温下只给6到8小时，严重创伤的“黄金一小时”，脓毒性休克的“Hour-1 Bundle”，允许性低血压的“90分钟手术限时”——这些数字不是背景信息，而是决策算法的输入参数。代谢时钟的概念统一了原本分属不同章节的内容，使得不同领域的决策逻辑可以在同一个时间轴上进行比较。同时，这个框架也揭示了技术进步的真正方向：从麻醉解放手术时间，到损伤控制收回时间，到常温机械灌注购买时间，再到可编程器官试图重新定义时间的刻度。外科的拥塞控制（Surgical Congestion Control）将TCP网络拥塞控制的逻辑迁移到外科决策中形成的跨学科分析框架。TCP的AIMD算法（加性增、乘性减）的核心是：当网络出现拥塞信号时，发送方主动降低速率，而非继续增加重传。损伤控制复苏的逻辑与此同构：当创伤患者的生理信号显示系统濒临崩溃时，外科团队主动降低干预强度，而非继续“加码”。两者共享的原理是：在过载状态下，最大的风险不是做得不够，而是做得太多。该类比在临床上的失效边界已被标注：DCR的“过载信号”滞后于损伤，暂停的代价不可逆，且外科不能“关闭”某个器官来保护整体。可编程器官（Programmable Organs）一个正在形成中的统一框架，将异种移植（基因编辑猪器官）、3D生物打印器官、器官机械灌注等看似不同的技术路径统一在“从生物学匹配到工程学设计”的范式下。基因编辑的“编程”是基因组层面的（不可逆、高门槛），3D打印的“编程”是结构层面的（可迭代、中等门槛），NMP的“编程”是灌注液成分层面的（可实时调节、低门槛）。这一概念的核心是：器官的特性可以被按需设计、版本迭代，而不再完全依赖自然赋予的生物学随机性。时间预算（Time Budget）外科决策中一个隐性但持续运行的认知框架：每一个可干预窗口都携带一个不可协商的代谢倒计时，外科医生在这个倒计时内决定“做什么”和“不做什么”。时间预算的概念不仅适用于创伤（黄金一小时）、移植（冷缺血时间）、麻醉（手术时间）等时间敏感的领域，也适用于肿瘤外科（术前预康复窗口、术后辅助治疗时机）和围手术期（ERAS路径的时间优化）。技术进步的实质，往往不是“做得更好”，而是“买到了更多时间”，或者“把时间约束从一个地方转移到了另一个地方”。第4章 麻醉、疼痛与围手术期处理麻醉前评估（Preoperative Anesthesia Evaluation）在麻醉实施前对患者进行的系统性评估，核心任务是识别可能影响麻醉安全的风险因素。评估内容涵盖既往麻醉史（尤其是困难气道、恶性高热、术中知晓等并发症）、用药史、过敏史、气道解剖（Mallampati分级、张口度、甲颏距离、颈部活动度）、心肺肝肾功能、ASA分级以及禁食状态。其核心原则是：评估比用药更重要。一个完整的麻醉前评估能够预判大部分麻醉风险，并制定相应的预案。ASA体格状态分级（ASA Physical Status Classification）美国麻醉医师协会制定的患者术前状态分级系统，从ASA I（健康病人）到ASA VI（脑死亡器官捐献者），用于将患者状态压缩为一个通用的沟通数字。ASA分级与围手术期死亡率的相关性被反复验证，说明“病人本身的状况”比“手术的难度”更能预测结局。但该分级有一个常被忽视的局限：评估者间一致性在ASA II和III的边界上是最大的，不同麻醉医生对同一病人可能给出不同分级。困难气道（Difficult Airway）麻醉中最危险的紧急状态之一，指经过常规培训的麻醉医师在面罩通气或气管插管时遇到困难的情况。其极端形式是“不能插管、不能通气”（CICV），可在数分钟内导致不可逆脑损伤或死亡。处理原则包括：预先准备困难气道车（视频喉镜、纤维支气管镜、喉罩、环甲膜切开套件），对预期极度困难的气道采用“清醒插管”技术，一旦失败不能反复尝试。核心规则是：无法氧合比无法插管更致命。快速序贯诱导（Rapid Sequence Induction, RSI）一种用于饱胃或存在反流误吸风险患者的麻醉诱导技术。核心步骤包括：预给氧（去氮），快速给予催眠药和肌松药（通常为琥珀胆碱或罗库溴铵），在环状软骨压迫下完成气管插管，以最小化从意识消失到气道保护之间的时间窗口。在创伤患者中，RSI需要同时兼顾颈椎保护（手法保持颈椎中立位）。术中知晓（Intraoperative Awareness）全身麻醉中患者意外恢复意识并可回忆术中事件的并发症。发生率在全麻中约为0.1-0.2%，在高风险人群（心脏手术、产科、创伤）中升高。其核心特征是：感觉神经全部运行（能感知疼痛、听到声音），但运动神经完全麻痹（无法睁眼、无法呼吸、无法求救、无法动弹）。这是“技术成功但体验失败”的典型——生命体征平稳，但病人经历了一场无法动弹的清醒创伤。预防措施包括麻醉深度监测（BIS等，但证据不一致）、避免全凭肌松、检查输注通路。靶控输注（Target-Controlled Infusion, TCI）一种基于药代动力学模型精确控制药物血浆浓度的给药方式。麻醉医师不再凭感觉推药，而是设定目标血浆浓度，由泵根据药代动力学模型计算输注速率。TCI使麻醉开始变成一门可计算的工程学科，是麻醉从“艺术”走向“工程”的第二次范式跃迁。闭环麻醉（Closed-Loop Anesthesia）一种AI算法根据实时监测指标（如BIS）自动调节麻醉药物输注的系统。以5-15秒的更新频率微调药物剂量，目标是将麻醉深度维持在预设范围内。当前处于SAE自动驾驶分级的L2级——“机器负责微调，人类掌控全局”。闭环系统的核心优势不在于算法精度，而在于它没有人类医生“宁深勿浅”的心理包袱，从而避免了不必要的深度麻醉。舒更葡糖钠（Sugammadex）一种选择性肌松结合剂（环糊精衍生物），能快速、完全地拮抗罗库溴铵与维库溴铵的肌松作用，显著快于新斯的明，尤其在深度肌松时。它的出现改变了“深度肌松不敢用”的局面。但并非没有代价：FDA不良事件数据显示其过敏反应发生率为0.3%，部分事件表现为心动过速、心动过缓甚至心脏骤停。在资源有限的环境中，其价格是新斯的明的数十倍，可及性受到严重限制。椎管内麻醉（Neuraxial Anesthesia）包括蛛网膜下腔阻滞（腰麻）和硬膜外阻滞。腰麻起效快、阻滞完善、用药量小；硬膜外可置管连续给药，适用于长时间手术与术后镇痛。核心生理影响是交感神经阻滞，导致静脉扩张、回心血量减少、低血压。最严重的并发症是硬膜外血肿，在使用抗凝药物的病人中风险显著升高。ASRA 2025年指南给出了详细的抗凝药与椎管内穿刺间隔时间：预防性低分子肝素至少停药12小时（bid）或24小时（qd），华法林需INR≤1.4，DOAC至少72小时。局麻药全身毒性（Local Anesthetic Systemic Toxicity, LAST）局麻药误入血管、过量或吸收过快导致的中枢和心脏毒性反应。表现为先中枢（口周麻木、耳鸣、意识改变、惊厥）后心脏（心肌抑制、心律失常、心跳骤停）。布比卡因的心脏毒性特别强且复苏困难。特效治疗是脂肪乳剂（20% intralipid）静脉输注，机制被认为是“脂肪池”效应。这是麻醉学中少有的“特异性解毒剂”。多模式镇痛（Multimodal Analgesia）现代术后镇痛的核心策略：联合使用作用机制不同的镇痛药与技术，产生协同镇痛，同时减少单一药物的剂量与副作用。组成包括区域阻滞/局部浸润、对乙酰氨基酚、NSAIDs、COX-2抑制剂、阿片类、氯胺酮、加巴喷丁类、右美托咪定、利多卡因静脉输注等。核心目标是“阿片节约”（opioid-sparing），因为阿片类药物的呼吸抑制、肠麻痹、谵妄、耐受与痛觉过敏、成瘾风险都是真实且严重的代价。术后慢性疼痛（Chronic Post-Surgical Pain, CPSP）手术后持续≥2-3个月、排除其他原因的疼痛。发生率因术式差异巨大：截肢（50%-85%）、开胸（5%-65%）、心脏手术（30%-55%）、乳腺手术（20%-50%）。机制涉及神经损伤、中枢敏化和炎症。危险因素包括术前已有疼痛、术后急性痛控制不佳、心理因素。预防重于治疗：围手术期优化镇痛是预防CPSP最有效的手段。加速康复外科（Enhanced Recovery After Surgery, ERAS）由丹麦外科医生Henrik Kehlet在1990年代提出的一套基于证据的围手术期管理方案，目的是减少手术应激、维持生理功能、加速康复。核心要素涵盖术前（预康复、缩短禁食、不常规肠道准备）、术中（微创技术、短效麻醉药、目标导向液体治疗、维持正常体温、多模式镇痛）和术后（早期进食、早期下床、早期拔管）。其真正意义在于：把几十项分散的措施打包成一个方案，用数据证明了系统性的优化优于任何单项的技术改进。围手术期（Perioperative Period）以手术治疗为中心的全过程。有两种并行定义：“时段型”（从确定手术治疗时至治疗基本结束，常量化为术前5-7天至术后7-12天）和“路径型”（从决定手术至康复出院的全过程）。ERAS指南要求术前戒烟戒酒4周、术前营养支持7-10天，这些措施的最短执行周期已经超过“5-7天”的定义边界。一旦采纳ERAS，围手术期就不再是时间段，而变成一条临床路径。驱动压（Driving Pressure）机械通气中平台压与PEEP之差，即 ，等于潮气量除以呼吸系统顺应性。近年来被认为与ARDS预后强相关，驱动压<15 cmH₂O被认为更安全。这提示“潮气量应按顺应性调整，而非按体重”。是肺保护性通气策略中的核心参数之一。每搏量变异度（Stroke Volume Variation, SVV）通过动脉波形计算得到的动态前负荷指标，反映在正压通气周期中每搏量的变异程度。SVV、PPV、被动抬腿试验等动态指标优于CVP等静态指标，因为它们“看反应”而非“看数值”。核心概念是“容量反应性”：给容量后每搏量增加≥10-15%者为有反应者，只有约50%的低血压病人对补液有反应。第5章 外科休克、感染与MODS休克（Shock）急性循环功能衰竭，导致组织灌注不足，不能满足细胞代谢需要，进而引起细胞与器官功能障碍。定义中最重要的部分是“组织灌注不足”而非“低血压”。低血压不等于休克，休克可以血压正常。休克的本质是氧供不能满足氧耗需求。根据血流动力学特征分为四种基本类型：低血容量性、分布性、心源性和梗阻性。但临床现实是：多数休克是混合性的。氧供与氧耗（DO₂ / VO₂）氧供（DO₂）= 心输出量 × 动脉血氧含量 × 10，反映单位时间内输送至组织的氧总量。氧耗（VO₂）= 心输出量 ×（动脉血氧含量 − 静脉血氧含量）× 10，反映组织实际消耗的氧量。氧摄取率（O₂ER）= VO₂/DO₂，正常约25-30%。当DO₂下降时，机体通过提高O₂ER代偿；当O₂ER已达极限而DO₂继续下降，VO₂开始依赖DO₂（氧供依赖性），此时发生无氧代谢与乳酸升高。这就是“隐性休克”的生理基础。隐性休克（Cryptic Shock）血压正常、SpO₂正常，但乳酸升高、ScvO₂降低、组织缺氧的状态。代偿期休克通过外周血管收缩维持血压，但组织已在缺氧。“看起来还行”是最危险的假象，此时的识别依赖心率、尿量、乳酸、精神状态、毛细血管再充盈，而非血压。允许性低血压（Permissive Hypotension）在活动性出血未控制时，主动维持一个较低的血压目标（如收缩压80-90 mmHg或可触及脉搏、意识清楚），以减少出血量、避免稀释性凝血病，直到出血被手术/介入控制。这是“控制性复苏”的核心策略。但它的证据基础并不坚实：三十年的RCT没有给出确定答案。例外情况：颅脑损伤病人不适用（需维持脑灌注压），有冠心病者需谨慎。损伤控制复苏（Damage Control Resuscitation, DCR）一种针对严重创伤出血的复苏策略，核心原则包括：允许性低血压、全血优先（或1:1:1比例的血制品输注）、限制晶体液、早期氨甲环酸、纠正致死三角。DCR的逻辑与网络工程中的拥塞控制同构：在系统过载时，主动降低干预强度，而非继续“加码”。脓毒症（Sepsis）Sepsis-3定义：感染引起的宿主反应失调导致的危及生命的器官功能障碍。操作化定义为：疑似感染 + SOFA评分急性升高≥2分。这一定义将脓毒症从“炎症综合征”重新定义为“器官功能障碍”，是概念史上的重大转向。此前（1991-2016）使用SIRS标准，但SIRS过于敏感，在术后病人中几乎是常态，导致大量轻症被纳入。SOFA评分（Sequential Organ Failure Assessment）评估6个系统（呼吸、凝血、肝、循环、神经、肾）的器官功能障碍评分，每个0-4分，总分0-24。与死亡率强相关，动态变化比单次值更有价值。2025年10月JAMA刊发了SOFA-2评分体系，基于全球330万ICU患者数据，将肾脏参数从绝对肌酐值改为基于年龄、性别和基础肾功能调整的评估，消除了对女性、老年人和慢性肾病患者的结构性偏倚。qSOFA（Quick SOFA）Sepsis-3提出的快速筛查工具，符合≥2项提示高风险：呼吸频率≥22次/分、意识改变（GCS<15）、收缩压≤100 mmHg。但qSOFA的敏感性较低，新南威尔士州临床卓越委员会在2016年明确表示不采纳qSOFA作为识别工具。CMAJ 2018的边界声明指出：新定义与标准“尚未被证明对个体患者的管理有用”。脓毒性休克（Septic Shock）脓毒症 + 在充分容量复苏后仍需升压药以维持MAP≥65 mmHg且血乳酸>2 mmol/L。在血流动力学上属于分布性休克，但在临床定义上是一个独立的诊断实体，住院死亡率>40%。集束化治疗（Sepsis Bundle）将脓毒症的救治措施打包成一个有时限的流程，核心是压缩从识别到干预的时间。Hour-1 Bundle包括：测量乳酸、使用抗生素前获取血培养（但不延误超过45分钟）、使用广谱抗生素、对低血压或乳酸≥4 mmol/L者开始快速补液（30 mL/kg晶体液）、若液体复苏后仍低血压则使用血管加压药。2026年版SSC指南将抗生素时机从“一刀切的1小时”转向“概率与严重度的双重分层”。感染源控制（Source Control）脓毒症治疗中最关键、最不可替代的措施：脓肿引流、坏死组织清创、感染的器械/导管拔除、梗阻解除、切除感染源。“源头不控制，抗生素无效”是外科感染的铁律。坏死性筋膜炎（Necrotizing Fasciitis）沿筋膜平面快速扩散的坏死性软组织感染，外科最凶险的感染之一。早期表现与蜂窝织炎几乎相同，关键鉴别征象包括：疼痛程度与皮肤表现不成比例、皮肤感觉异常/麻木、皮肤变紫/水疱/捻发感、快速进展、全身中毒症状重。LRINEC评分敏感性约70-80%，特异性约85-90%，不能作为排除依据。“探查”是金标准。治疗三支柱：早期广泛反复的手术清创、广谱抗生素、重症支持。这是一个“宁可错杀”的领域——临床怀疑本身就是足够强的手术指征。多器官功能障碍综合征（Multiple Organ Dysfunction Syndrome, MODS）在严重感染、创伤、休克等急性打击后，机体同时或序贯出现两个或以上器官系统的功能障碍。它是ICU病人死亡的主要原因，核心机制是“失控的全身炎症反应 + 微循环障碍 + 线粒体功能障碍”。分为原发性和继发性两类，后者与“二次打击学说”相关：第一次打击“激活”了炎症系统，第二次打击（感染、手术、缺血再灌注）触发失控。急性呼吸窘迫综合征（Acute Respiratory Distress Syndrome, ARDS）柏林标准（2012）定义：已知临床诱因后1周内发生，双肺浸润影不能完全用积液/肺不张/结节解释，不能完全用心衰或液体过负荷解释，氧合障碍按PaO₂/FiO₂分级（轻度200-300，中度100-200，重度≤100）。病理生理核心是弥漫性肺泡损伤。“婴儿肺”概念是其小潮气量通气的理论基础：ARDS时可有效通气的肺组织显著减少，看似正常的潮气量施加在小肺上就是过度牵张。弥散性血管内凝血（Disseminated Intravascular Coagulation, DIC）由多种病因引起的、以全身凝血系统激活为特征的获得性综合征，导致微血管血栓形成、凝血因子与血小板消耗、继发性纤溶亢进。脓毒症是最常见病因。分期在教学中清晰，在临床中模糊：高凝期没有可用的常规实验室标志，临床上看到的第一眼往往已经是消耗性低凝期。ISTH显性DIC积分：血小板计数、D-二聚体、PT延长、纤维蛋白原，≥5分诊断。持续床旁血液净化（Continuous Renal Replacement Therapy, CRRT）一种缓慢、持续、对血压影响小的血液净化模式。原理包括弥散（清除小分子）、对流（清除中分子）、吸附（部分细胞因子和药物）。常用剂量20-25 mL/kg/h。“血液净化清除炎症介质”这一设想的失败是重症医学最重要的教训之一：机制合理，但临床未证实获益——炎症介质的产生远超清除速度，且可能清除了有益的介质。心肺脑复苏（Cardiopulmonary Cerebral Resuscitation）包括基本生命支持（BLS）、心脏进一步生命支持（ACLS）和复苏后生命支持。BLS的核心是“C-A-B”：胸外按压（频率100-120次/分，深度5-6 cm，充分回弹，尽量减少中断）、开放气道、人工呼吸。高质量CPR是复苏成功最重要的决定因素。可逆原因的搜索用“Hs and Ts”框架：低血容量、缺氧、酸中毒、高/低钾、低体温；张力性气胸、心脏压塞、中毒、肺栓塞、冠脉血栓。目标体温管理（Targeted Temperature Management, TTM）将心搏骤停后复苏患者的核心温度控制在32-36°C，持续至少24小时，然后缓慢复温。TTM-2研究（2021）显示33°C与≤37.5°C的常温管理在死亡与神经结局上无显著差异，当前共识转向“避免发热”至少与低温同样重要。复苏后生命支持（Post-Cardiac Arrest Care）决定最终结局的关键阶段，包括：目标体温管理、血流动力学优化（MAP≥65 mmHg）、氧合与通气（避免低氧与高氧）、血糖控制、神经功能评估与预后判断。预后判断必须延迟（复温后至少72小时），且需多模态评估。最重要的伦理陷阱是“自我实现预言”：如果因为预测预后不良而撤除治疗，那么“预后不良”的预测就会被实现。第6章 急性组织损伤：创伤、烧伤与急腹症损伤控制外科（Damage Control Surgery, DCS）一种分期手术策略：第一次手术只做“救命”的三件事——止血、控制污染、临时关闭，目标手术时间≤90分钟。然后送ICU纠正生理紊乱（复温、纠酸、纠正凝血病），待稳定后再行确定性手术。核心洞察是：外科医生最大的诱惑——“一次做完”——在严重创伤中恰恰是致命的。能做完整手术，不等于应该做完整手术。致死三角（Lethal Triad）低体温、酸中毒、凝血病三者互相加重形成的恶性循环。核心温度<35°C时凝血功能显著受损，pH<7.2时凝血因子活性下降约50%。三者都不是原始损伤，而是修复过程本身诱发的次生失效。打断循环的方法：保温、纠正灌注、补充凝血因子与血小板与钙、纠正酸中毒。创伤性凝血病（Trauma-Induced Coagulopathy, TIC）创伤后早期即存在的凝血功能障碍，不是“输多了液体才稀释出来的”。机制包括：组织损伤释放组织因子导致DIC样消耗，休克导致蛋白C激活与纤溶亢进，血小板功能障碍，纤维蛋白原消耗，低体温与酸中毒。2025年1月Critical Care系统综述显示，早期纤维蛋白原替代与死亡率、DVT或输血需求之间并无显著关联——“发现异常”与“补充是否改善结局”是两个不同层次的问题。黄金一小时（Golden Hour）由R. Adams Cowley在1970年代提出的临床直觉，而非RCT结论。这个概念在创伤急救中获得了极高的叙事权重，但2025-2026年的证据显示其适用范围比原先认为的窄得多：出血性休克患者确实存在时间-结果关系，但创伤性脑损伤患者中，院前时间与结果之间没有一致关系。“黄金一小时”正在被拆解为“分类型的黄金窗口”。xABCDEATLS第11版（2025年）对经典ABCDE流程的改写。其中“x”代表“控制致命性出血”（exsanguinating haemorrhage），被置于气道之前。逻辑翻转的核心是：可压迫的四肢出血和可填塞的躯干出血在数分钟内即可致死，而气道梗阻的致死窗口通常以十分钟计。先堵住“漏”，再通“气”。各机构执行细节略有差异：ACS官方写作xABCDE，Mayo Clinic写作xABDCE。核心原则一致。FAST / eFASTFAST（Focused Assessment with Sonography for Trauma）是床旁超声快速探查腹腔/心包游离液体的技术，优点是快速、可重复、不搬动病人。eFAST增加了胸腔（气胸、血胸）评估。局限是对空腔脏器损伤与腹膜后不敏感。创伤铁律：“不稳定 + 阳性FAST → 直接开腹”。损伤控制骨科（Damage Control Orthopaedics, DCO）长骨骨折先行外固定，待生理稳定后再行髓内钉。适用于休克、酸中毒、凝血病、严重胸部损伤、严重颅脑损伤者。与“早期完全固定”的选择需个体化。烧伤九分法（Rule of Nines）成人烧伤面积估算方法：头颈部9%，双上肢18%，躯干27%，双下肢（含臀部）46%。小儿面积分布不同：头颈部面积 = 9 + (12 − 年龄)%，双下肢面积 = 46 − (12 − 年龄)%。手掌法：病人本人一个手掌（含手指）约占体表面积1%。Parkland公式烧伤补液最常用的公式：第一个24小时乳酸林格液量 = 4 mL × 体重(kg) × 烧伤面积(%TBSA)。前8小时给一半（从烧伤时刻起算，而非入院时刻），剩余16小时给另一半。核心原则是“公式是起点，不是终点”——真正的目标是尿量（成人0.5 mL/kg/h，小儿1 mL/kg/h）。2024年ABA指南已建议将初始复苏剂量改为2ml/kg/%TBSA作为起始估算。焦痂切开（Escharotomy）环形深度烧伤导致组织压升高、影响循环或通气时，沿肢体长轴切开焦痂至深筋膜的紧急措施。指征包括远端脉搏消失/减弱、毛细血管再充盈消失、肢体发凉发绀、筋膜室压力升高。与“筋膜切开”（fasciotomy）的区别：焦痂切开是切开坏死皮肤的束缚，筋膜切开是切开深筋膜的。电烧伤（Electrical Burn）特殊性在于皮肤入口与出口的损伤程度完全不能反映深部组织的损伤。机制：电流通过组织产生焦耳热（Q = I²Rt），电阻高的组织产热多（骨 > 肌腱 > 脂肪 > 皮肤 > 肌肉 > 血管 > 神经）。肌肉大量坏死导致肌红蛋白尿和急性肾损伤。处理要点：心肺监护、积极补液（目标尿量75-100 mL/h）、碱化尿液、筋膜切开、早期探查与清创。急腹症（Acute Abdomen）急性腹痛是急诊最常见的主诉之一，也是外科最需要“在不确定中行动”的领域。腹痛定位遵循胚胎来源：上腹正中（前肠）、脐周（中肠）、下腹（后肠）。内脏痛定位模糊，躯体痛定位精确。核心诊断原则是“动态再评估”：一个腹痛4小时的病人，8小时后再查一次，答案常常就清楚了。观察本身就是一种积极的诊疗行为。腹膜刺激征压痛、反跳痛、肌紧张三联征，提示壁层腹膜受刺激。但在镇静/肌松后消失，老年人和免疫抑制病人可表现不明显。这是外科急腹症中最重要的体格检查发现。消化道大出血上消化道出血（Treitz韧带以上）与下消化道出血（Treitz韧带以下）。最重要原则：按“复苏—诊断—止血”的顺序，但三者尽可能并行，且在出血未控制前，复苏永远优先于诊断。Forrest分级用于溃疡出血的内镜治疗决策：Ia（喷射性）、Ib（渗血）、IIa（可见血管残端）、IIb（附着血凝块）需内镜治疗；IIc（黑色基底）、III（无出血征象）不需。第7章 肿瘤切除与器官移植前哨淋巴结活检（Sentinel Lymph Node Biopsy, SLNB）原理：肿瘤的淋巴引流有顺序，第一个接受引流的淋巴结（前哨淋巴结）若为阴性，则后续淋巴结转移的概率极低。技术在肿瘤周围注射示踪剂（蓝色染料和/或放射性核素），术中探测“热”与“蓝”的淋巴结。意义：用1-3个淋巴结的状态，替代对20-30个淋巴结的清扫，是“以最小创伤获得最多信息”的典范。应用于乳腺癌和黑色素瘤。R0 / R1 / R2切除肿瘤手术切缘的病理学分级：R0（切缘无肿瘤）、R1（镜下切缘阳性）、R2（肉眼残留）。不同器官的“足够切缘”不同：乳腺癌保乳为“no ink on tumor”，结直肠癌需关注环周切缘（CRM），软组织肉瘤需广泛切除（假包膜外的正常组织袖）。观察等待（Watch and Wait）器官保留的极致形式：用于直肠癌新辅助放化疗后达到临床完全缓解的病人，不手术，改为严密随访。若复发再行挽救手术。理论基础是病理完全缓解者手术无获益，而手术有明确的功能与并发症代价。这是“不做手术”成为一种积极治疗选项的最激进例证。肿瘤标志物（Tumor Markers）由肿瘤细胞或宿主对肿瘤的反应产生的、可在体液中检测的物质。三个用途：辅助诊断、疗效监测、复发监测。三个陷阱：假阳性、假阴性、过度诊断。“发现更多癌症”不等于“救更多命”——PSA筛查的悖论在于它显著增加了前列腺癌的检出率，却未能等比例降低死亡率。PSA筛查（PSA Screening）前列腺特异抗原筛查，1980年代引入后前列腺癌诊断率飙升，但大型RCT结论不一致，过度诊断率很高。目前的共识：PSA筛查应与病人充分讨论（共同决策），不推荐对预期寿命有限者常规筛查。大量被检出的惰性癌终生不会威胁生命，筛查带来的“生存获益”很大程度上是过度诊断导致的统计学假象。免疫检查点抑制剂（Immune Checkpoint Inhibitors）包括抗CTLA-4（伊匹木单抗）、抗PD-1（纳武利尤单抗、帕博利珠单抗）、抗PD-L1（阿替利珠、度伐利尤、阿维鲁）。已获批用于黑色素瘤、非小细胞肺癌、肾细胞癌、MSI-H/dMMR的所有实体瘤（不限癌种，这是革命性的）等。对外科医生的要求变化包括：认识免疫相关不良事件（irAE）、围手术期应激剂量激素、假性进展与真性进展的鉴别。HLA配型（HLA Matching）人类白细胞抗原（HLA）是移植配型的核心。HLA-I类（A、B、C）表达于所有有核细胞，HLA-II类（DR、DQ、DP）表达于抗原呈递细胞。HLA基因高度多态性，是移植配型困难的根本原因。肾移植HLA配型最重要，肝移植HLA匹配要求低（肝有“免疫特权”），造血干细胞移植HLA配型是关键中的关键。交叉配型（Crossmatch）受者血清与供者淋巴细胞反应，阳性=禁忌（预存抗HLA抗体→超急性排斥）。虚拟交叉配型：若受者HLA抗体谱明确且推测的供者HLA不与之反应，可免做实际交叉配型，扩大可接受的供者范围。免疫抑制（Immunosuppression）移植后终身服药的核心困境：免疫抑制越充分，排斥越少，但感染与肿瘤的风险越高；免疫抑制越弱，感染与肿瘤风险越低，但排斥与移植物失功的风险越高。移植病人生活在“排斥”与“感染”之间的狭窄走廊里。常用药物包括钙调磷酸酶抑制剂（他克莫司、环孢素）、抗代谢药（霉酚酸酯、硫唑嘌呤）、mTOR抑制剂（西罗莫司、依维莫司）、共刺激阻断剂（贝拉西普）。抗体介导的排斥（Antibody-Mediated Rejection, AMR）由供者特异性抗体（DSA）引起的排斥反应，诊断依据血清学DSA + 组织学证据（C4d沉积、微血管炎症）+ 临床功能障碍。治疗包括血浆置换、IVIG、抗CD20、抗补体、蛋白酶体抑制剂。AMR是移植领域最棘手的问题，因为产生抗体的浆细胞对常规免疫抑制相对抵抗。冷缺血时间（Cold Ischemia Time）从器官冷灌注开始到植入体内血流开放的时间。供肝≤12小时，供肾≤24小时，供心≤6小时，供肺≤8小时。这些时间限制决定了器官分配的地理半径：心脏（6-8h）半径最小、中心最少；肾脏（24h）半径最大，可跨省乃至跨国共享。常温机械灌注（Normothermic Machine Perfusion, NMP）在体外常温含氧条件下持续灌注供器官，替代静态冷保存。2025年RCT荟萃分析显示：NMP相比SCS，早期移植物功能障碍（EAD）16.4% vs 27.2%，器官利用率75.5% vs 69.4%，而患者生存率、移植物生存率无显著差异。NMP改善的是“器官能不能被用上”，而不是“用了之后活多久”。更深层含义：它把“冷缺血时间”从一个生理约束变成了一个经济约束。异种移植（Xenotransplantation）将动物（主要为基因编辑猪）器官移植到人体。Tim Andrews案例（2025年1月）：66岁终末期肾病患者接受69处基因编辑猪肾，存活271天后因MRSA感染后减药导致血栓性微血管病被摘除，82天后成功接受人类供体肾脏。西京医院案例（2025年3月）：亚洲首例基因编辑猪-人肾移植，六基因编辑猪，存活261天。桥接移植（Bridge to Allotransplantation）用异种器官作为临时替代，等待人类供体器官的过渡策略。“桥接”概念彻底改变了异种移植的定位：从“永久替代”降格为“过渡方案”。但这恰恰使其在伦理和技术上变得更加可行。不追求完美，只解决“等待中的死亡”。可编程器官（Programmable Organs）一个统一框架：基因编辑猪器官（基因组层面的编程）、3D生物打印器官（结构层面的编程）、器官机械灌注（灌注液成分层面的编程）。核心是从“生物学匹配”到“工程学设计”的范式转移。但终局有一个条件：技术的可及性。科学的天花板和物流的天花板，最终是同一个天花板——谁有能力支付它。CAR-T细胞治疗（Chimeric Antigen Receptor T-cell Therapy）嵌合抗原受体T细胞免疫疗法。传统CAR-T需采集患者T细胞，体外改造扩增后输回，等待2-4周，费用高昂。体内CAR-T通过载体将CAR基因直接送入患者体内的T细胞，省去体外步骤。2026年6月，科济药业舒瑞基奥仑赛注射液（CT041）获国家药监局批准上市，成为全球首款获批用于实体瘤的CAR-T细胞治疗产品，靶向CLDN18.2阳性、HER2阴性晚期胃/食管胃结合部腺癌，将中位生存期从不足4个月提升到近9个月。评分与分级系统GCS（Glasgow Coma Scale）睁眼（1-4）+ 言语（1-5）+ 运动（1-6），范围3-15。创伤评估中用于神经功能障碍评估。单侧瞳孔散大提示脑疝。ISS（Injury Severity Score）取身体三个最严重区域的AIS平方和，范围1-75。ISS > 15分定义为严重创伤。局限：在急诊早期无法准确计算，用于事后评估与质量改进。RTS（Revised Trauma Score）基于GCS、收缩压、呼吸频率的生理评分，范围0-12。在急诊即时可用，用于现场分诊与初期决策。LRINEC评分坏死性筋膜炎的实验室风险指标，基于CRP、白细胞、血红蛋白、血钠、肌酐、血糖。敏感性约70-80%，特异性约85-90%，不能作为排除依据。Forrest分级溃疡出血的内镜分级：Ia（喷射性出血）、Ib（渗血）、IIa（可见血管残端）、IIb（附着血凝块）、IIc（黑色基底）、III（无出血征象）。Ia-IIb需内镜治疗。MELD评分终末期肝病模型，用于肝移植分配：MELD = 3.78 × ln(胆红素) + 11.2 × ln(INR) + 9.57 × ln(肌酐) + 6.43。把“谁最需要肝”从主观判断变成了可计算的数字。Glasgow-Blatchford评分（GBS）消化道出血风险分层评分，基于血尿素氮、Hb、收缩压、脉搏、黑便、晕厥、肝病、心衰。用于判断是否需要入院/干预。ASA分级美国麻醉医师协会体格状态分级：ASA I（健康）至ASA VI（脑死亡器官捐献者），E为急诊后缀。ASA分级与围手术期死亡率的相关性被反复验证。SAE自动驾驶分级L0（无自动化）至L5（完全自动化）。当前闭环麻醉处于L2级——“机器负责微调，人类掌控全局”。该分级在汽车工程中本身有争议（L3的“人机交接”问题），迁移到麻醉领域时争议被放大。